Introduction
============

Breast cancer is the leading cause of cancer death among females worldwide and is a highly heterogeneous disease [@B1]. According to the expression status of the estrogen receptor α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), breast cancer is clinically classified into three main subtypes, including luminal (ERα/PR-positive), HER2-positive, and triple-negative breast cancer (TNBC) [@B2]. In general, luminal-type breast tumors have relatively good clinical outcomes with a lower chance of metastasis, whereas TNBC represents the most aggressive subtype of breast cancer with a higher incidence of early relapse, distant metastasis, and a worse prognosis [@B3], [@B4].

The phenotypic differences between distinct breast cancer subtypes are reflected in their diverse transcriptomic and proteomic profiles [@B5], [@B6]. Evidence shows that the differential patterns of transcript variant expression are sufficient to differentiate breast cancer subtypes [@B5]. Diverse transcript variants arise from alternative transcription initiation, splicing, and polyadenylation, and may give rise to distinct protein isoforms with diverse functions [@B7]. The alternative transcription initiation, also known as alternative promoter usage, results in multiple pre-mRNAs being transcribed from different transcription start sites within a gene locus [@B8]. This event may affect open reading frames in mRNAs and give rise to protein isoforms with different N-terminal sequences [@B9], [@B10]. In the mammalian genome, over 50% of the genes are regulated through alternative transcription initiation (7). Alternative splicing is a two-step biological process, in which the introns are removed and then different exons of the same gene are selectively joined together to generate multiple transcripts [@B11]. There are four main types of alternative splicing, including exon skipping, intron retention, mutually-exclusive exons, or alternative 5ʹ or 3ʹ splice site [@B12]. It is estimated that approximately 95% of the human multiexon genes undergo alternative splicing [@B13]. Alternative polyadenylation generates mRNAs with alternative 3\' ends and therefore potentially regulates the stability, localization, and translation efficiency of target RNAs [@B14]. Alternative transcription events are commonly deregulated in breast cancer, thus contributing to tumor initiation and progression, and providing potential therapeutic targets. For example, a switch from the CD44 variant isoform (CD44v) to the CD44 standard isoform (CD44s) is functionally essential for epithelial-mesenchymal transition and determines breast cancer stem cell state and metastasis [@B15]-[@B17]. In addition, specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are associated with breast cancer cellular sensitivity to therapeutic agents AZD6244, lapatinib, erlotinib, and paclitaxel, respectively [@B18]. Despite these important observations, the contribution of distinct transcript variants to breast cancer development and progression is not completely understood.

Chromodomain Y-like protein 2 (CDYL2) is a poorly characterized member of the chromodomain Y (CDY) protein family, which includes chromodomain Y (CDY) and chromodomain Y-like (CDYL) [@B19]. This family of proteins is characterized by the presence of two conserved functional domains, an N-terminal chromodomain (CD) and a C-terminal enoyl-coenzyme A hydratase (ECH) catalytic domain [@B19], [@B20]. The CD domain is present in multiple chromatin-binding proteins, such as the heterochromatin protein 1 (HP1), and is implicated in chromatin binding and the recognition of lysine-histone tails [@B21]. The ECH domain is commonly found in coenzyme A (CoA)-dependent acylation enzymes, which are biochemically linked to fatty acid metabolism and are associated with cancer progression and drug resistance [@B22]-[@B24]. Human CDY exhibits testis-specific expression, CDYL is ubiquitously expressed, whereas CDYL2 exhibits selective expression in tissues of testis, prostate, spleen, and leukocytes [@B19], [@B25]. Evidence from human and mouse studies suggests that genes in the CDY family play an important role in spermatogenesis [@B26], [@B27]. Recently, two RNA-sequencing (RNA-seq) based transcriptomic analyses demonstrated that CDYL2 is upregulated in CD133-positive colorectal cancer stem cells compared to CD133-negative counterparts [@B28], and that the exposure of rat serotonergic cells to valproic acid and lithium, two commonly used mood stabilizer drugs, results in downregulation of CDYL2 [@B29]. In addition, CDYL2 may affect susceptibility to inflammatory bowel disease in Koreans [@B30] and is potentially involved in osteoporosis pathogenesis [@B31]. However, the functional and mechanistic role for CDYL2 in human cancer remains unexplored.

It is increasingly recognized that many of the spermatogenesis-related genes have crucial functions in tumorigenesis and tumor progression [@B32], [@B33]. The analysis of publicly available databases demonstrates that CDYL2 not only is highly expressed in human testis tissues, but is also abundantly expressed in breast tumors. However, whether CDYL2 is involved in breast cancer development and progression remains unknown. In this study, we provide evidence for the first time that two CDYL2 transcript variants, named CDYL2a and CDYL2b, are predominantly expressed in human breast cancer cell lines and primary breast tumors and exert discrete functions in breast cancer growth and metastasis. These findings uncover an isoform-specific function of CDYL2 in breast cancer and highlight the importance of targeting key driver genes at the isoform level for breast cancer therapy.

Methods
=======

Cell culture and reagents
-------------------------

Human mammary epithelial cell line (HMEC), human embryonic kidney cell line (HEK293T), and eleven breast cancer cell lines used in this study were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cell lines were authenticated by routine detection of morphology, cell vitality, DNA fingerprinting, and mycoplasma, and were kept in culture for less than six months after receipt. SK-BR-3 and MDA-MB-468 cells were cultured in McCoy\'s 5A (\#L630) and Leibovitz\'s L-15 (\#L620) media (BasalMedia, Shanghai, China), respectively. Other cell lines were cultured in DMEM medium (\#L110, BasalMedia). All culture media were supplemented with 10% fetal bovine serum (\#FSS500, ExCell Biol, Shanghai, China) and 1% penicillin-streptomycin (\#S110B, BasalMedia).

Human tissue specimens
----------------------

Primary breast tumor samples and adjacent noncancerous breast tissues from patients diagnosed with invasive breast carcinoma were obtained from the Tissue Bank at Fudan University Shanghai Cancer Center under institutional guidelines. All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all patients prior to surgery. Immunohistochemistry evaluation of ERα, PR, and HER2 expression status was conducted as part of the routine diagnostic procedure to determine molecular subtypes of breast cancer at the Department of Pathology of Fudan University Shanghai Cancer Center.

DNA constructs, siRNAs, and transfection
----------------------------------------

CDYL2b cDNA was obtained from Vigene Bioscience (\#CH869225, Rockville, MD, USA) and subcloned into the lentiviral vector pCDH-CMV-MCS-EF1-Puro (\#CD510B-1, System Biosciences, Palo Alto, CA, USA) or pLVX-IRES-Neo (\#632181, Biofeng, Shanghai, China) to generate pCDH-Flag-CDYL2b or pLVX-Flag-CDYL2b. We amplified the common sequence between CDYL2a and CDYL2b and synthesized the unique 5\' sequence of CDYL2a (HuaGen Biotech, Shanghai, China). Then, we ligated those two sequences into pCDH-CMV-MCS-EF1-Puro or pLVX-IRES-Neo vector to produce Flag-CDYL2a using ClonExpress II One Step Cloning Kit (\#C112-02, Vazyme Biotech, Nanjing, China). The short hairpin RNA (shRNA) sequences targeting human CDYL2 were obtained from BLOCK-iT RNAi Designer (<http://rnaidesigner.thermofisher.com/> rnaiexpress/) and then cloned into pLKO.1-TRC vector (\#10878, Addgene, Watertown, MA, USA). The cDNAs of HPSE (\#CH806645), HLA-F (\#CH864022) and SELL (\#CH832492) were purchased from Vigene Bioscience. The detailed information of expression vectors and primers used in molecular cloning is provided in **[Tables S1](#SM0){ref-type="supplementary-material"} and S2**. All small interfering RNAs (siRNAs) and negative control siRNA (siNC) were purchased from Ribobio (Beijing, China) and their target sequences are listed in **[Table S3](#SM0){ref-type="supplementary-material"}**.

To generate stable cell lines, plasmid constructs or shRNAs in lentiviral expression vectors were transfected into HEK293T together with packaging plasmid mix using Neofect DNA transfection reagent (\#TF20120, TengyiBio, Shanghai, China). The supernatant containing viruses was harvested 48 h after transfection and used to infect cells in the presence of 8 μg/mL of polybrene (\#H9268, Sigma-Aldrich, St. Louis, MO, USA). After 24 h of infection, cells were selected with 2 μg/mL of puromycin (\#13884-500, Cayman Chemical, Ann Arbor, MI, USA). The siRNAs were transfected into cells using Lipofectamine 2000 (\#11668019, Invitrogen, Carlsbad, CA, USA) at a final concentration of 50 nM.

RNA extraction, RT-PCR, and qPCR
--------------------------------

Total RNA was isolated from cultured cells and tissue samples using TRIzol reagent (\#15596018, Invitrogen) and cDNA was synthesized using PrimeScript RT Master Mix (\#RR036A, Takara, Dalian, China). PrimeSTAR Max DNA polymerase (\#RR045A, Takara) was used for conventional RT-PCR assays. PCR products were separated by electrophoresis on a 2% agarose gel or subjected to sequencing. Quantitative real-time PCR (qPCR) was performed in triplicates using TB Green Premix Ex Taq (\#RR420A, Takara) on an Eppendorf Realplex qPCR machine. All the primers were synthesized by HuaGene Biotech and their sequences are available in **[Table S4](#SM0){ref-type="supplementary-material"}**. The 2^-ΔΔCT^ method was used to determine the relative detection level of each mRNA in cell lines and clinical tissue samples [@B34].

Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR)
----------------------------------------------------------

SimpleChIP Plus Sonication Chromatin IP (\#56383S, Cell Signaling Technology, Danvers, MA, USA) was used for ChIP assays according to the manufacturer\'s protocol. Approximately 1 × 10^7^ cells were cross-linked in 1% formaldehyde for 10 min at room temperature and quenched in glycine for 5 min. The solubilized chromatin was incubated with antibodies against Flag and IgG. The ChIP-qPCR primers are listed in **[Table S4](#SM0){ref-type="supplementary-material"}**.

RNA-seq and ATAC-Seq
--------------------

RNA-seq was performed as described previously [@B35]. Briefly, RNA-seq library construction was performed using VAHTS mRNA-seq V2 Library Prep Kit for Illumina (\#NR601-01, Vazyme), followed by sequencing using the Illumina sequencing platform. Sequenced reads were aligned to the hg38 genome assembly using HISAT2 software. Analyses for differential gene expression and alternative splicing were performed with DESeq2 and MISO as described previously [@B35]. Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) was performed according to a published protocol [@B36]. Briefly, about 1 × 10^5^ cells were washed with PBS and lysed with lysis buffer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl~2~, 0.1% NP-40, 1X protease inhibitor). Then, the nuclei were resuspended in 25 μL TD buffer, 24 μL lysis buffer, and 1 μL TDE1 enzyme for 30 min at 55 °C. DNA was extracted and sequenced.

Antibodies, immunoblotting, immunoprecipitation, and immunofluorescent staining
-------------------------------------------------------------------------------

All antibodies used in this study are listed in **[Table S5](#SM0){ref-type="supplementary-material"}**. For immunoblotting analysis, cells were lysed in RIPA buffer. Equal amounts of proteins were separated by SDS-PAGE and transferred onto a PVDF membrane (\#IPVH00010, Millipore, Billerica, MA, USA). The membranes were incubated with the appropriate primary antibodies and detected with the enhanced chemiluminescence detection kit (\#36208ES80, Yeasen, Shanghai, China). For immunoprecipitation (IP) assays, cellular extracts were incubated with primary antibodies in a rotating incubator at 4°C overnight, followed by incubation with protein A/G magnetic beads (\#B23202, Bimake, Houston, TX, USA) for another 2 h. The immunoprecipitate was washed three times and analyzed through immunoblotting. For immunofluorescent staining, cells were fixed with 4% paraformaldehyde, premeabilized in 0.1% Triton X-100, and blocked with 10% normal goat serum in PBST. Then, cells were incubated with the corresponding primary antibodies, washed three times using PBST, and incubated with second antibodies conjugated with Alexa Fluor 555 (\#4409S or \#4413S, Cell Signaling Technology) or Alexa Fluor 488 (\#4408S or \#4412S, Cell Signaling Technology). DNA was stained with fluoroshield mounting medium with DAPI (\#ab104139, Abcam, Cambridge, MA, USA). Leica SP5 confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany) was used for imaging.

Cell proliferation and colony formation assays
----------------------------------------------

Cell proliferation assays were conducted using the Cell Counting Kit-8 (CCK-8) (\#CK04, Dojindo Laboratories, Kumamoto, Japan). For colony formation assays, 1000 cells (8000 cells for BT20 cell line) were plated into 6-well plates in triplicates and cultured in normal conditions for 2 weeks. Colonies were fixed in methanol and stained with 0.5% crystal violet. Colonies with more than 50 cells were counted.

Wound-healing, cell migration, and invasion assays
--------------------------------------------------

For wound-healing assays, cells were seeded in 6-well plates and a scratch was made using a 200 μL pipette tip. Cells were then washed with PBS and incubated in medium containing 0.1% FBS for the indicated times. For migration and invasion assays, 2 × 10^4^ cells in serum-free media were plated in the upper chambers coated with (invasion) or without (migration) growth factor-reduced Matrigel (\#354480 and \#353097, respectively, Corning, New York, NY, USA). After 24 h or 48 h, cells in the lower membranes of transwell chambers were fixed in methanol, stained with 0.5% crystal violet, and counted under a microscope.

Xenograft tumors in nude mice
-----------------------------

All animal experiments were performed in compliance with the guidelines of the Institutional Animal Care and Use Committee at Fudan University. For subcutaneous inoculation, 5×10^6^ MDA-MB-231 cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b in 200 μL PBS were injected subcutaneously into the mammary fat pad of 6-week-old BALB/c female nude mice (State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China). The tumor volume was measured twice a week and calculated with the formula (length×width^2^)/2. The mice were killed eight weeks later and tumors were removed and weighed individually. For experimental lung metastasis assays, 1.5 × 10^6^ MDA-MB-231 cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b in 200 μL PBS were injected into the tail veins of 6-week-old BALB/c female nude mice. Six weeks after the injection, mice were sacrificed, the lungs were removed, and metastatic nodules were counted.

Statistical analyses
--------------------

All data are presented as the mean ± standard error from at least three independent experiments unless otherwise indicated. The unpaired two-tailed Student\'s *t* test was used to compare data between two groups. *P* values of less than 0.05 were considered statistically significant.

Results
=======

CDYL2a and CDYL2b are the predominant isoforms expressed in breast cancer cell lines and tumors
-----------------------------------------------------------------------------------------------

In support of its potential role in spermatogenesis, analyses of the Human Protein Atlas (HPA) database [@B37] revealed that CDYL2 was primarily expressed in human testis, placenta, and prostate tissues, with extremely high expression levels in the testis (**[Figure S1](#SM0){ref-type="supplementary-material"}**). As many of spermatogenesis-related genes are reactivated in human cancer [@B32], [@B33], we further examined the expression patterns of CDYL2 in breast cancer. Analyses of multiple publicly available databases, including ONCOMINE [@B38], Expression Profiling Interactive Analysis (GEPIA) [@B39], and The Cancer Genome Atlas (TCGA) [@B40], revealed that the mRNA levels of CDYL2 were significantly higher in breast tumor tissues than those in normal breast tissues (**[Figure S2](#SM0){ref-type="supplementary-material"}-4**). Analyses of The Clinical Proteomic Tumor Analysis Consortium (CPTAC) database [@B41] also revealed that the protein levels of CDYL2 were upregulated in breast tumors relative to normal breast tissues (**[Figure S5](#SM0){ref-type="supplementary-material"}**). These bioinformatic analyses data prompted us to further investigate whether CDYL2 is involved in breast cancer development and progression.

Human CDYL2 pre-mRNA contains ten exons and generates four transcript variants, named CDYL2a (GenBank Accession No. XM_011522866.1), CDYL2b (NM_152342.4), CDYL2c (XM_011522867.2), and CDYL2d (XM_024450151.1), which share the last six exons (exons 5-10) with only differences in their first exons (**[Figure S6](#SM0){ref-type="supplementary-material"}A**). Those four transcripts encode four different protein isoforms, which consist of 540, 506, 503, and 447 amino acid residues with a predicted molecular weight of 59.4, 55.7, 55.3, and 49.2 kDa, respectively (**[Figure S6](#SM0){ref-type="supplementary-material"}B**). CDYL2a, CDYL2b, and CDYL2c proteins contain intact CD domain and ECH domain but differ in their N-terminal sequences. The CDYL2d isoform remains the C-terminal ECH domain but lacks the N-terminal CD domain (**[Figure S6](#SM0){ref-type="supplementary-material"}B**). Close inspection of the genomic and protein sequence revealed that the CDYL2b transcript variant corresponds to the CDYL2 cDNA and that the CDYL2b protein isoform corresponds to the CDYL2 protein documented in UniProtKB database (Q8N8U2).

To examine the expression pattern of those four transcripts in human breast cancer cell lines and tumor tissues, we first performed qPCR analyses using isoform-specific primers. Results showed that the human mammary epithelial cell line HMEC and eleven breast cancer cell lines primarily expressed CDYL2a and CDYL2b isoforms (**Figure [1](#F1){ref-type="fig"}A**). In contrast, CDYL2c and CDYL2d isoforms were barely detectable in these cell lines, suggesting that those two isoforms, if they are present, do not play a prominent role in breast cancer pathogenesis. In addition, we noticed that the expression levels of CDYL2b were significantly lower in the majority of TNBC cell lines (with the exception of BT20 cell line) than those in luminal and HER2-positive breast cancer cell lines [@B42] (**Figure [1](#F1){ref-type="fig"}A**). To further validate these results, conventional RT-PCR analysis was performed using RNA extracted from MCF-7 cells and the resultant PCR products were subjected to agarose gel electrophoresis and sequencing. Results showed that only CDYL2a and CDYL2b cDNAs were amplified in MCF-7 cells (**[Figure S7](#SM0){ref-type="supplementary-material"}A**). Sequencing of the PCR products further demonstrated that the sequences of CDYL2a and CDYL2b were identical to the ones documented in the NCBI database (**[Figure S7](#SM0){ref-type="supplementary-material"}B-C**).

Next, we examined the expression status of the four CDYL2 transcripts in sixty pairs of primary breast tumor tissues and adjacent noncancerous breast tissues (twenty pairs for luminal, HER2-positive, and TNBC subtypes, respectively) and found that primary breast tumors mainly expressed CDYL2a and CDYL2b (**Figure [1](#F1){ref-type="fig"}B**). Moreover, CDYL2a was upregulated in the majority of the breast tumors relative to matched normal breast tissues (**Figure [1](#F1){ref-type="fig"}C**). In contrast, CDYL2b was mainly upregulated in luminal and HER2-positive breast tumors relative to TNBC tumors (**Figure [1](#F1){ref-type="fig"}D**), which is consistent with the expression pattern of CDYL2 in the TCGA database (**[Figure S4](#SM0){ref-type="supplementary-material"}C**).

To analyze the protein expression levels of different CDYL2 isoforms in human breast cancer cell lines and breast tumors, we conducted immunoblotting analyses using a commercial CDYL2 antibody (\#ab183854, Abcam). This antibody was generated using a recombinant fragment within the human CDYL2 aa 1-351 and the exact sequence is proprietary. As the CDYL2a protein contains the same N-terminal 351 aa as CDYL2b does (**[Figure S6](#SM0){ref-type="supplementary-material"}B**), this CDYL2 antibody is able to recognize both CDYL2a and CDYL2b proteins. As shown in **Figure [1](#F1){ref-type="fig"}E**, two main bands were observed in HMEC and eleven breast cancer cell lines. According to the predicted molecular weight, the upper and lower bands corresponded to CDYL2a (about 59.4 kDa) and CDYL2b (about 55.7 kDa), respectively. This conclusion was further confirmed by subsequent experiments with overexpression of CDYL2a and CDYL2b. In addition, we noticed that CDYL2a protein levels were upregulated in most breast cancer cell lines. In contrast, CDYL2b was upregulated in luminal-type and HER2-positive breast cancer cell lines, but was downregulated in most TNBC cell lines compared to the HMEC cell line (**Figure [1](#F1){ref-type="fig"}E**). In fourteen pairs of clinical samples, CDYL2a and CDYL2b were upregulated in 57.1% (8/14) and 35.7 % (5/14) of the primary breast tumors relative to matched normal breast tissues, respectively (**Figure [1](#F1){ref-type="fig"}F**). Collectively, these results suggest that breast cancer cell lines and breast tumor tissues primarily express CDYL2a and CDYL2b.

CDYL2a plays a growth-promoting role, whereas CDYL2b exerts an antimetastatic role in breast cancer progression
---------------------------------------------------------------------------------------------------------------

To delineate the biological functions of CDYL2a and CDYL2b in breast cancer development and progression, we stably expressed Flag-CDYL2a and Flag-CDYL2b in MDA-MB-231 and Hs578T cells, which express relatively low levels of endogenous CDYL2a and CDYL2b (**Figure [1](#F1){ref-type="fig"}E**), through lentiviral infection. The expression status of CDYL2a and CDYL2b in those two cell lines was determined by immunoblotting with an anti-Flag antibody (**Figure [2](#F2){ref-type="fig"}A**). CCK-8 (**Figure [2](#F2){ref-type="fig"}B**) and colony formation (**Figure [2](#F2){ref-type="fig"}C-D**) assays demonstrated that the ectopic expression of CDYL2a enhanced the proliferation and colony formation capability of MDA-MB-231 and Hs578T cells compared to empty vector controls. In contrast, overexpression of CDYL2b did not have this effect (**Figure [2](#F2){ref-type="fig"}B-D**). To investigate whether CDYL2a and CDYL2b might regulate tumorigenic capacity of breast cancer cells *in vivo*, MDA-MB-231 cells stably expressing the empty vector pCDH, Flag-CDYL2a, or Flag-CDYL2b were subcutaneously injected into mammary fat pads of 6-week-old female BALB/c nude mice. In support of *in vitro* findings, tumors from CDYL2a overexpressing MDA-MB-231 cells grew much faster at the implantation sites than in their control cells (**Figure [2](#F2){ref-type="fig"}E**); this faster growth was accompanied with an increase in the tumor volume (**Figure [2](#F2){ref-type="fig"}F**) and weight (**Figure [2](#F2){ref-type="fig"}G**). This phenomenon was not observed in tumors from CDYL2b overexpressing cells (**Figure [2](#F2){ref-type="fig"}E-G**). Collectively, these results suggest that CDYL2a promotes breast cancer cell proliferation and colony formation *in vitro* and xenograft tumor growth *in vivo*.

As one of the key features of breast cancer cells is their invasive and metastatic behavior [@B43], we further examined whether CDYL2a and CDYL2b might modulate the invasive and metastatic phenotype of breast cancer cells. Wound-healing assays showed that CDYL2b overexpressing MDA-MB-231 and Hs578T cells had a lower closure of the wound area compared to that of the control cells (**Figures [2](#F2){ref-type="fig"}H and S8A**). In contrast, the ectopic expression of CDYL2a did not significantly affect cell migration (**Figures [2](#F2){ref-type="fig"}H and S8A**). These results were further confirmed with Boyden\'s chamber migration assays (**Figure [2](#F2){ref-type="fig"}I-J**). Moreover, MDA-MB-231 and Hs578T cells stably expressing CDYL2b showed a reduced invasion in Matrigel-coated invasion chambers (**Figure [2](#F2){ref-type="fig"}I-J**). These results indicate that CDYL2b, but not CDYL2a, suppresses breast cell migration and invasion *in vitro*. To examine whether CDYL2b affects the metastatic potential of breast cancer cells *in vivo*, MDA-MB-231 cells stably expressing the empty vector pCDH, Flag-CDYL2a, or Flag-CDYL2b were injected into nude mice through tail veins. As shown in **Figure [2](#F2){ref-type="fig"}K-L**, CDYL2b-overexpressing cells significantly decreased the number of metastatic tumors in the lungs of mice as compared with that of empty vector-expressing cells. Collectively, these results establish that CDYL2b suppresses breast cancer cell migration and invasion *in vitro* and the formation of lung metastases in experimental lung metastasis mouse models.

As the CDYL2b transcript variant corresponds to the CDYL2 cDNA, we analyzed the relation between CDYL2 expression levels and the prognosis in patients with breast cancer *via* the Kaplan-Meier plotter database [@B44]. Results showed that high expression of CDYL2 was associated with better relapse-free survival (RFS) of all patients with breast cancer (**[Figure S8](#SM0){ref-type="supplementary-material"}B**). Subgroup analyses based on molecular subtypes of breast tumors showed that high CDYL2b expression was significantly associated with better RFS in patients with luminal A, luminal B, and basal-like tumors but not in HER2-positive ones (**[Figure S8](#SM0){ref-type="supplementary-material"}C**). These results highlight a discrete function of CDYL2b in different subtypes of breast cancers. It is noteworthy mentioning that currently no CDYL2a expression information is available in the Kaplan-Meier plotter database, thus we failed to analyze the association between CDYL2a expression levels and the prognosis of patients with breast cancer.

To further confirm isoform-specific functions of CDYL2, we knocked down CDYL2 in BT20 and MCF-7 cell lines, both expressing CDYL2a and CDYL2b isoforms, by lentiviral infection with expression vectors encoding shRNA targeting CDYL2 (shCDYL2) and negative control shRNA (shNC). Worthy of note, we were not able to design specific shRNA sequences targeting only CDYL2a or CDYL2b due to a tiny discrepancy in the unique sequence of CDYL2a or CDYL2b mRNA. Immunoblotting analysis showed that shCDYL2 \#1 and shCDYL2 \#5 efficiently knocked down CDYL2a and CDYL2b in both cell lines, and the knockdown efficacy of shCDYL2 \#5 was better than that of shCDYL2 \#1 (**Figure [3](#F3){ref-type="fig"}A**). As a control, both shCDYL2 \#1 and shCDYL2 \#5 did not significantly affect the expression levels of CDYL, a closely related member of the CDY family [@B19] (**Figure [3](#F3){ref-type="fig"}A**). The knockdown effects mediated by shCDYL2 \#1 and shCDYL2 \#5 were also validated by qPCR analysis (**[Figure S9](#SM0){ref-type="supplementary-material"}A**). Moreover, we reconstituted CDYL2a and CDYL2b into CDYL2-depleted BT20 and MCF-7 cells by lentiviral infection, and selected the stable clones in which the levels of CDYL2a and CDYL2b overexpression were comparable to those of endogenous CDYL2a and CDYL2b in both cell lines for subsequent functional studies (**Figure [3](#F3){ref-type="fig"}B**). CCK-8 and colony formation assays revealed that the knockdown of CDYL2 suppressed cell proliferation and colony formation capacity of BT20 and MCF-7 cells (**Figure [3](#F3){ref-type="fig"}C-E**), and the effects were restored by re-expression of CDYL2a but not CDYL2b (**Figure [3](#F3){ref-type="fig"}F-H**). Cells expressing shCDYL2 exhibited higher migratory and invasive ability than shNC expressing control cells (**Figures [3](#F3){ref-type="fig"}I-K and S9B**). Moreover, shCDYL2-mediated increase in cell migration and invasion was compromised by the reconstitution of CDYL2b, but not CDYL2a, into cells expressing shCDYL2 (**Figures [3](#F3){ref-type="fig"}L-N and S9C**).

To further validate the above results, we repeated those assays in BT549 and HCC1806 cell lines, which predominately express CDYL2a. Results showed that the knockdown of CDYL2a (**[Figure S10](#SM0){ref-type="supplementary-material"}A-B**) resulted in a decrease in cell proliferation (**[Figure S10](#SM0){ref-type="supplementary-material"}C**) and colony formation capacity of BT549 and HCC1806 cells (**[Figure S10](#SM0){ref-type="supplementary-material"}D**), but did not significantly affect their migratory and invasive potential (**[Figure S10](#SM0){ref-type="supplementary-material"}E-F**). Collectively, these results demonstrated that CDYL2a promotes breast cancer cell proliferation, whereas CDYL2b suppresses breast cancer cell migratory and invasive behaviors.

CDYL2a partially localizes to nuclear speckles while CDYL2b is localized in the heterochromatin
-----------------------------------------------------------------------------------------------

Protein subcellular localization is intimately linked to protein functions in health and disease. To examine the subcellular localization of CDYL2a and CDYL2b, we transfected Flag-CDYL2a or Flag-CDYL2b into MDA-MB-231 and Hs578T cells and then conducted immunofluorescent staining with the appropriate antibodies. Results showed that both CDYL2a and CDYL2b were present in the nucleus but localized to distinct nuclear subcompartments. In this context, CDYL2b was co-localized with the histone H3 trimethylation at lysine 9 (H3K9me3) and the heterochromatin protein 1α (HP1α), two hallmarks of the heterochromatin (**Figure [4](#F4){ref-type="fig"}A-B**). This result is consistent with a recent report showing that CDYL2 co-localizes with H3K9me3 [@B20]. Immunoprecipitation (IP) assays further demonstrated that CDYL2b, but not CDYL2a, interacted with H3K9me3 (**[Figure S11](#SM0){ref-type="supplementary-material"}A**). In contrast, CDYL2a was distributed in a speckle-like pattern in the nucleus and did not co-localize with HP1α, H3K9me3, and DAPI (**Figure [4](#F4){ref-type="fig"}A-B**). In addition to chromatin, the nucleus contains several types of nuclear subcompartments (or nuclear bodies), such as nucleolus, nuclear speckles, promyelocytic leukemia (PML) bodies, paraspeckles, and Cajal bodies [@B45]. Markers for those nuclear compartments have been well established and demonstrated to be applicable for co-localization studies in living cells [@B46]. Further studies revealed that CDYL2a was partially co-localized with the spliceosomal protein SC35 (also known as serine-and-arginine-rich splicing factor 2, SRSF2), an established nuclear speckle marker [@B46] (**Figure [4](#F4){ref-type="fig"}C**). We also confirmed the interaction between CDYL2a and SC35 with IP assays (**[Figure S11](#SM0){ref-type="supplementary-material"}B**). In addition, CDYL2a did not localize to other nuclear bodies, as it lacked co-localization with the nucleolar proteins fibrillarin (FBL) and nucleophosmin (NPM) (**Figures [4](#F4){ref-type="fig"}D and S11C**), PML body marker PML protein (**[Figure S11](#SM0){ref-type="supplementary-material"}D**), paraspeckle marker non-POU domain-containing octamer-binding protein (NONO) (**[Figure S11](#SM0){ref-type="supplementary-material"}E**), and Cajal body formatting protein Coilin (**[Figure S11](#SM0){ref-type="supplementary-material"}F**). Collectively, these results demonstrated that CDYL2a and CDYL2b localize to distinct subnuclear compartments, which may be relevant to their nuclear functions.

CDYL2a promotes breast cancer cell proliferation through regulating alternative splicing of FIP1L1, NKTR, and ADD3 genes
------------------------------------------------------------------------------------------------------------------------

Nuclear speckle, also known as splicing speckle, is a subnuclear compartment enriched in small ribonucleoprotein particles and various splicing factors and is involved in splice site selection in both constitutive and alternative splicing [@B45]. As CDYL2a is localized in SC35-positive nuclear speckles, we then examined whether CDYL2a affects alternative splicing events of its target genes. To do this, Hs578T cells stably expressing pCDH, Flag-CDYL2a, and Flag-CDYL2b were subjected to RNA-seq to define potential alternative splicing events. Using a cutoff of false discovery rate (FDR) \< 5% and absolute ΔPSI (percentage of spliced in) value \> 0.1, we identified thirty-four and eleven alternative splicing events in CDYL2a- and CDYL2b-overexpressing cells, respectively (**Figure [5](#F5){ref-type="fig"}A**). The main type of these identified splicing events was exon skipping. According to absolute ΔPSI value, we selected four genes that were detected in CDYL2a overexpressing cells with remarkable exon skipping for further validation, including the factor interacting with PAPOLA and CPSF1 (FIP1L1), the natural killer cell triggering receptor (NKTR), adducin 3 (ADD3), and the ATP synthase F1 subunit gamma (ATP5F1C) (**Figure [5](#F5){ref-type="fig"}B**). For convenience of description, we referred to the longer isoform of those four genes as L and to the shorter isoform as S. The skipping of FIP1L1 (exon 13), NKTR (exon 6), ADD3 (exon 15), and ATP5F1C (exon 9) was further demonstrated by qPCR with exon-specific primers, as the ratio of L isoforms to all isoforms (L plus S isoforms) of those genes was consistently downregulated in CDYL2a-overexpressing MDA-MB-231 and Hs578T cells (**Figure [5](#F5){ref-type="fig"}C**). In contrast, overexpression of CDYL2a did not affect the total isoform levels of FIP1L1, NKTR, ADD3, and ATP5F1C (**[Figure S12](#SM0){ref-type="supplementary-material"}**). In support of the above results, knockdown of CDYL2 with two different shRNAs resulted in upregulation of L isoforms of FIP1L1, NKTR, ADD3, and ATP5F1C in BT20 and MCF-7 cells (**Figure [5](#F5){ref-type="fig"}D**). Furthermore, the isoform switch of FIP1L1, NKTR, ADD, and ATP5F1C from L isoforms to S isoforms was further demonstrated by conventional RT-PCR in Hs578T cells (**Figure [5](#F5){ref-type="fig"}E**). We then detected those four splicing events in primary breast tumors, which highly expressed CDYL2a (**Figure [1](#F1){ref-type="fig"}D**). Results showed that the exon skipping events of FIP1L1, NKTR, and ADD3, but not ATP5F1C, occurred in most tumor tissues highly expressing CDYL2a compared to matched normal breast tissues (**[Figure S13](#SM0){ref-type="supplementary-material"}A**). Following these observations, we analyzed the exon skipping events of FIP1L1, NKTR, and ADD3 in tumor samples from the above xenograft tumor models (**Figure [2](#F2){ref-type="fig"}E**). Overexpression of CDYL2a resulted in a decrease in the L isoform levels of FIP1L1, NKTR, and ADD3 genes (**[Figure S13](#SM0){ref-type="supplementary-material"}B**).

FIP1L1 is a component of the cleavage and polyadenylation specificity factor (CPSF) and is associated with two leukemogenic fusion genes, the FIP1L1-retinoic acid receptor alpha (RARA) and the FIP1L1-platelet-derived growth factor receptor alpha (PDGFRA), thus contributing to the pathogenesis of distinct types of leukemia [@B47], [@B48]. In addition, genetic alterations of FIP1L1 are associated with survival of patients with gliomas [@B49]. NKTR is required for natural killer-like activity in human T cells [@B50] and is supposed to be involved in tumor growth inhibition in a SP2/0 myeloma model [@B51]. ADD3 is a subunit of adducins [@B52] and its alternative splicing events have been reported in HER2-positive breast cancer [@B53] and in non-small cell lung cancer [@B54]. A recent study revealed that miR-145 may suppress the activity of ADD3 and inhibit the proliferation of glioblastoma cells [@B55]. To test whether CDYL2a enhances breast cancer proliferation through regulating the levels of the L isoforms of those three genes, we knocked down the L isoforms of the genes by siRNAs (**[Figure S14](#SM0){ref-type="supplementary-material"}A-C**). CCK-8 cell proliferation assays showed that knockdown of the L isoforms of FIP1L1, NKTR, and ADD3 might compromise shCDYL2-mediated inhibitory effects on cell proliferation of both BT20 and MCF-7 cells (**Figure [5](#F5){ref-type="fig"}F**). Collectively, these results suggest that CDYL2a promotes breast cancer cell proliferation through, at least partly, regulating the alternative splicing of FIP1L1, NKTR, and ADD3 genes.

CDYL2b suppresses breast cancer cell migration and invasion through transcriptional inhibition of several metastasis-promoting genes
------------------------------------------------------------------------------------------------------------------------------------

As CDYL2b localizes to heterochromatin that plays important roles in transcriptional silencing, we investigated whether it suppresses breast cancer cell invasive and metastatic potential by transcriptional repression of target genes. To test this notion, we analyzed the above-generated RNA-seq data from Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b and focused on genes that were only affected by ectopic expression of CDYL2a or CDYL2b. Genes with FDR \< 5% and log~2~ fold change (FC) \> 1 or \<-1 were considered differentially expressed. Results showed that 92.5% (568/614) and 61.0% (278/456) of the genes were downregulated in CDYL2b- and CDYL2a-expressing cells, respectively (**Figure [6](#F6){ref-type="fig"}A-B**). Gene ontology (GO) enrichment analyses revealed that CDYL2a regulating genes were involved in biological processes such as fat cell differentiation, cellular protein metabolism, inflammatory response, positive regulation of axonogenesis, and endothelial cell proliferation (**[Figure S15](#SM0){ref-type="supplementary-material"}A**). In contrast, genes regulated by CDYL2b were mainly involved in transcription regulation, cell migration, and cell adhesion (**[Figure S15](#SM0){ref-type="supplementary-material"}B**), supporting a role for CDYL2b in regulating gene transcription and cell migration.

Transcriptionally repressed genes are often organized within "closed" chromatin domains, marked by different histone modifications, such as H3K9me3. Given that CDYL2b co-localizes and interacts with H3K9me3 (**Figures [4](#F4){ref-type="fig"}A and S11A**), we surmised that CDYL2b may affect chromatin accessibility. To test this notion, Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were subjected to ATAC-seq, a powerful method to examine genome-wide chromatin accessibility [@B36]. We considered peaks with FDR \< 5% and fold change \> 2 or \<0.5 as differentially accessible. ATAC-seq identified 1451 differentially accessible peaks in CDYL2b expressing cells compared to pCDH expressing control cells. Out of them, 96.8% (1405/1452) of the differentially accessible peaks were less accessible and 3.2% (47/1452) were more accessible in CDYL2b expressing cells, respectively. These results support a main role of CDYL2b as a repressor of transcription. Integrative analysis of ATAC-seq and RNA-seq data found that thirty-eight genes had significant reduced expression levels and decreased chromatin accessibility in cells expressing CDYL2b compared to those in pCDH- and CDYL2a- expressing cells (**Figure [6](#F6){ref-type="fig"}C**). According to the fold change of downregulated genes and decreased peaks in CDYL2b overexpressing cells compared to cells expressing pCDH, we chose three genes, heparanase (HPSE), major histocompatibility complex class I, F (HLA-F), and selectin L (SELL) for further validation (**Figure [6](#F6){ref-type="fig"}C-D**). qPCR analysis demonstrated that the expression levels of HPSE, HLA-F, and SELL were downregulated in both MDA-MB-231 and Hs578T cells expressing CDYL2b but not CDYL2a (**Figure [6](#F6){ref-type="fig"}E**). Depletion of CDYL2 by two independent shRNAs resulted in the upregulation of HPSE, HLA-F, and SELL in both BT20 and MCF-7 cells (**Figure [6](#F6){ref-type="fig"}F**). To further validate these results, we examined the expression levels of HPSE, HLA-F, and SELL in primary breast tumors with high CDYL2b expression (**Figure [1](#F1){ref-type="fig"}B**). Results showed that the expression levels of HPSE, HLA-F, and SELL were downregulated in most tumor tissues with high CDYL2b expression compared to the expression levels in matched normal breast tissues (**[Figure S16](#SM0){ref-type="supplementary-material"}A**). Consistently, reduced expression of HPSE, HLA-F, and SELL was also observed in CDYL2b-overexpressing xenograft tumors as compared with pCDH expressing controls (**[Figure S16](#SM0){ref-type="supplementary-material"}B**). Collectively, these results suggest that CDYL2b represses HPSE, HLA-F, and SELL expression.

Since CDYL2b may bind to H3K9me3, we hypothesized that CDYL2b may be recruited to the H3K9me3 containing promoter region of those three genes, resulting in transcription repression of their expression. To test this hypothesis, we analyzed the H3K9me3 enrichment regions at the promoters of these three genes at the UCSC website and designed four qPCR primers at the corresponding sites (**[Figure S17](#SM0){ref-type="supplementary-material"}A**). ChIP-qPCR was performed using Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b. Results showed that CDYL2b was enriched at least in one H3K9me3-containing region of these promoters. In contrast, CDYL2a was not enriched at these regions (**[Figure S17](#SM0){ref-type="supplementary-material"}B**). These experiments showed that CDYL2b might bind to the H3K9me3 region of HPSE, HLA-F, and SELL promoters, thus repressing their expression.

Previous studies have found that HPSE and SELL can promote the invasion and metastasis of cancer cells, and the expression of HLA-F is closely related to the invasion of cancer [@B56]-[@B58]. To further verify that CDYL2b affects the migratory and invasive potential of breast cancer cells through transcriptional repression of HPSE, HLA-F, and SELL, we conducted rescue experiments by restoring HPSE, HLA-F, and SELL expression in MDA-MB-231 and Hs578T cells stably expressing CDYL2b (**Figure [7](#F7){ref-type="fig"}A**). Transwell cell migration and invasion assays showed that overexpression of CDYL2b in MDA-MB-231 and Hs578T cells suppressed breast cancer migration and invasion, which was partially rescued by expressing HPSE, HLA-F, and SELL in these cells (**Figure [7](#F7){ref-type="fig"}B-C**). These data confirmed once again that CDYL2b may affect the invasion and metastasis of breast cancer cells through, at least partly, transcriptional repression of HPSE, HLA-F, and SELL.

Discussion
==========

In this study, we report for the first time that two CDYL2 transcript variants, CDYL2a and CDYL2b, were differentially expressed in human breast cancer cell lines and primary breast tumors, and exerted discrete functional and mechanistic roles in breast cancer growth and metastasis through different molecular mechanisms.

Data indicate that spermatogenesis and carcinogenesis share a number of biological processes, such as cell survival, migration, and genome maintenance [@B32]. Consequently, many of the transiently expressed genes in developing germ cells act as proto-oncogenes and oncogenes in various types of human cancers [@B32], [@B33]. For instance, the fibrous sheath interacting protein 1 (FSIP1), a spermatogenesis related testicular antigen, is aberrantly expressed in breast cancer and regulates its growth and invasiveness [@B59]. The sperm-associated antigen 1 (SPAG1) contributes to the early spread and poor prognosis of pancreatic adenocarcinoma [@B60]. In addition, the spermatogenesis-associated protein 2 (SPATA2) has been shown to be a novel predictor of the outcome in ovarian cancer [@B61]. The human genome encodes three CDY family proteins, including one on the Y chromosome (CDY) and two on autosomes (CDYL and CDYL2) [@B19]. CDY is expressed exclusively in the testis [@B25] and has an important role in spermatogenesis [@B62]. In addition, CDYL enables to regulate histone acetylation and crotonylation during spermatogenesis [@B27]. Consequently, knockout of CDYL results in a severe progressive infertility in male mice due to the deficiency in spermatogonia maintenance [@B26]. Recently, a gene expression profiling study identified CDYL as one of the fourteen differentially expressed genes between breast tumors with and without visceral metastatic disease [@B63]. In addition, CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27me3 at the cyclin dependent kinase inhibitor 1C (CDKN1C) promoter [@B64]. However, the functional and mechanistic role for CDYL2 in human cancer remains unexplored. In this study, we provided evidence that CDYL2 might generate four transcript variants (**[Figure S6](#SM0){ref-type="supplementary-material"}**). The most frequently and highly expressed CDYL2 variants in breast cancer cell lines and primary breast tumors were CDYL2a and CDYL2b. Especially, CDYL2a was upregulated in the majority of breast cancer cell lines and primary breast tumors, while CDYL2b was mainly expressed in luminal and HER2-positive ones (**Figure [1](#F1){ref-type="fig"}**). Functionally, CDYL2a played a protumorigenic role, whereas CDYL2b had an antimetastatic function in breast cancer progression (**Figure [2](#F2){ref-type="fig"}-[3](#F3){ref-type="fig"}**).

The different subcellular locations of protein isoforms may contribute to its functional diversity. In our study, we found that CDYL2a partially co-localized with SC35, a well-established marker for nuclear speckles [@B46] (**Figure [4](#F4){ref-type="fig"}**). Nuclear speckles are nuclear domains enriched in pre-mRNA splicing factors and are involved in splicing regulation [@B45]. Among these different modes of alternative splicing, exon skipping accounts for 40% of the entire alternative splicing events [@B65]. Mechanistic investigations further revealed that CDYL2a was involved in regulating exon skipping events of its target genes, including FIP1L1, NKTR, and ADD3 (**Figure [5](#F5){ref-type="fig"}**). In support of our findings, an exon skipping event of FIP1L1 has been documented in colon cancer [@B66]. NK-TR is specifically expressed in natural killer (NK) cells and is required for NK-like activity in human T cells [@B50]. A recent study shows that the 5\' region of the NK-TR mRNA has two sites of alternate splicing, and interleukin 2 (IL-2) regulates the expression of the NK-TR gene via an alternate RNA splicing mechanism [@B67]. In addition, ADD3 alternative splicing events have been reported in HER2-positive breast cancer [@B53] and in non-small cell lung cancer [@B54]. However, the detailed mechanism by which the alternative splicing of those three genes regulates breast cancer growth certainly deserves further investigation.

A recent study demonstrated that CDYL2 is mainly localized in the nucleus and interacts with H3K9me3 [@B20]. In our study, we found that the subcellular localization of CDYL2b was similar to the one of CDYL2, as reported previously [@B20]. CDYL2b might bind to the H3K9me3 and transcriptionally repressed several metastasis-promoting genes, such as HPSE, HLA-F, and SELL (**Figure [6](#F6){ref-type="fig"}**). It has been reported that the HPSE levels in sera of patients with breast cancer are much higher than those in benign breast disease and healthy people [@B68] and HPSE may promote bone metastasis of breast cancer but not the tumor growth [@B69]. In addition, microRNA-1258 can inhibit the expression and enzymatic activity of HPSE and thus suppress the brain metastasis of breast cancer [@B70]. HLA-F is a member of the non-classical HLA class I molecules. The expression of HLA-F closely correlates with nodal involvement, lymphatic invasion, venous invasion, and poor prognosis in patients with gastric cancer [@B58]. In gliomas, the expression of HLA-F also correlates with malignant phenotype and poor overall survival [@B71]. In stage II breast cancer, overall survival of patients with HLA-F expression is lower than the one in those without HLA-F expression [@B72]. SELL also participates in breast cancer metastasis. Depletion of SELL inhibits migration but not the proliferation of MDA-MB-231 cells [@B57]. Hence, CDYL2b might regulate the migration, invasion, and metastasis of breast cancer through, at least partly, regulating HPSE, HLA-F, and SELL expression.

One unanswered question in this study is how CDYL2a and CDYL2b transcript variants are regulated during breast cancer progression. For alternative splicing, 99% of all exons are flanked by the intronic dinucleotides GT and AG at the 5\' and 3\' splice sites, respectively [@B73]. Bioinformatic analyses revealed the absence of canonical (GT-AG) and non-canonical (GC-AG) splice sites in the exon-intron boundary at the first four exons of CDYL2 (data not shown), arguing against a role for splicing in their generation. Analysis of the promoter sequence of CDYL2a and CDYL2b using the UCSC Genome Browser database found that their promoter regions contain multiple transcription factor binding sites (data not shown), indicating that these transcription factors may alternatively use the distinct transcription start sites to induce CDYL2a and CDYL2b expression. However, the detailed mechanism underlying the generation of CDYL2a and CDYL2b in human breast cancer cell lines and breast tumors remains to be investigated in the near future.

Conclusions
===========

In summary, findings presented suggest that CDYL2 transcript variants exert discrete roles in breast cancer growth and metastasis through differentially regulating alternative splicing and transcription events. These findings suggest that the pharmacological inhibition of CDYL2a but not CDYL2b isoform would be an effective strategy for breast cancer therapy.
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![**CDYL2a and CDYL2b are the predominant isoforms expressed in human breast cancer cell lines and breast tumors.** (A-B) qPCR analysis of the relative mRNA expression levels of four CDYL2 transcription variants in the indicated cell lines (A) and 60 primary breast tumor samples (20 samples for luminal, HER2-positive, and TNBC subtype, respectively). The relative expression levels of CDYL2a, CDYL2b, CDYL2c, and CDYL2d mRNA were first normalized to the GAPDH levels. Then, CDYL2a was used as a control in each breast cancer cell line (A) and breast tumor sample (B) as it was detectable in all samples. (C-D) qPCR analysis of the relative mRNA expression levels of CDYL2a (C) and CDYL2b (D) in 60 pairs of primary breast tumor tissues and matched normal breast tissues (20 samples for luminal, HER2-positive, and TNBC subtype, respectively). The expression levels of CDYL2a (C) or CDYL2b (D) in normal tissues were used as a control after normalization to the GAPDH levels. (E) Immunoblotting analysis of CDYL2 protein expression in the indicated cell lines with an anti-CDYL2 antibody. Vinculin was used as a loading control. (F) Immunoblotting analysis of CDYL2 protein expression in 14 pairs of primary breast tumor tissues and matched normal breast tissues with an anti-CDYL2 antibody. Vinculin was used as a loading control.](thnov10p5242g001){#F1}

![**CDYL2a promotes breast cancer cell proliferation and tumor growth while CDYL2b suppresses breast cancer cell migratory, invasive, and metastatic potential.** (A) Establishment of stable MDA-MB-231 and Hs578T cells expressing pCDH, Flag-CDYL2a, and Flag-CDYL2b by lentiviral infection. The expression status of Flag-CDYL2a and Flag-CDYL2b in these cell lines was validated by immunoblotting analysis with an anti-Flag antibody. Vinculin was used as a loading control. (B-D) MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were subjected to cell proliferation assays using CCK-8 (B) and colony formation assays (C-D). Representative images of the colonies (C) and quantitative results (D) are shown. (E-G) MDA-MB-231 cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were injected into mammary fat pads of 6-week-old female BALB/c nude mice (n = 6). After 8 weeks of injections, xenograft tumors were harvested. Photographs of harvested tumors (E), tumor growth curves (F), and tumor weights (G) are shown. (H-J) MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were subjected to wound-healing assays (H), Boyden\'s chamber migration assays and Matrigel-coated invasion assays (I and J). Representative images of the wound-healing assays are included in Supplementary [Figure S8](#SM0){ref-type="supplementary-material"}A and the corresponding quantitative results are shown in H. Representative images of Transwell migration and invasion assays are shown in I and the corresponding quantitative results are shown in J. (K-L) MDA-MB-231 cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were injected into 6-week-old female BALB/c nude mice (n = 6) through the tail vein. After 6 weeks of injections, the lungs were harvested. Representative images of lung metastasis (K) and quantitative results of lung nodules (L) are shown. NS, are not significant differences; \*, \*\*, and \*\*\* are significant differences at *p*\<0.05, *p*\< 0.01, and *p*\<0.001 levels, respectively.](thnov10p5242g002){#F2}

![**Re-expression of CDYL2a restores the impaired cell proliferation of CDYL2-depleted cells, while re-expression of CDYL2b reverses the enhanced cell migratory and invasive potential of CDYL2-depleted cells.** (A) Immunoblotting analysis of CDYL2 protein expression in BT20 and MCF-7 cells stably expressing shNC, shCDYL2 \#1, or shCDYL2 \#5 with an anti-CDYL2 antibody. Vinculin was used as a loading control. (B) CDYL2-depleted BT20 and MCF-7 cells were reconstituted with Flag-CDYL2a or Flag-CDYL2b by lentiviral infection. The expression status of CDYL2a and CDYL2b in these cell lines was validated with immunoblotting analysis using an anti-CDYL2 antibody. Vinculin was used as a loading control. (C-E) BT20 and MCF-7 cells stably expressing shNC, shCDYL2 \#1, or shCDYL2 \#5 were subjected to cell proliferation assays using CCK-8 (C) and colony growth assays (D-E). Representative images of the colonies (D) and quantitative results (E) are shown. (F-H) CDYL2-depleted BT20 and MCF-7 cells were reconstituted with Flag-CDYL2a and Flag-CDYL2b by lentiviral infection and then subjected to cell proliferation assays using CCK-8 (F) and colony growth assays (G-H). Representative images of the colonies (G) and quantitative results (H) are shown. (I-K) BT20 and MCF-7 cells stably expressing shNC, shCDYL2\#1, or shCDYL2\#5 were subjected to wound-healing assays (I), Boyden\'s chamber migration assays and Matrigel-coated invasion assays (J-K). Representative images of wound-healing assays are shown in Supplementary [Figure S9](#SM0){ref-type="supplementary-material"}B and the corresponding quantitative results are shown in I. Representative images of Transwell migration and invasion assays are shown in J and the corresponding quantitative results are shown in K. (L-N) CDYL2-depleted BT20 and MCF-7 cells were reconstituted with Flag-CDYL2a and Flag-CDYL2b by lentiviral infection and then subjected to wound-healing assays (L), Boyden\'s chamber migration assays, and Matrigel-coated invasion assays (M-N). Representative images of wound-healing assays are shown in Supplementary [Figure S9](#SM0){ref-type="supplementary-material"}C and the corresponding quantitative results are shown in L. Representative images of Transwell migration and invasion assays are shown in M and corresponding quantitative results are shown in N. \*\* and \*\*\* are significant differences at *p*\<0.01 and *p*\<0.001, respectively.](thnov10p5242g003){#F3}

![**Subcellular localization of CDYL2a and CDYL2b.** (A-D) MDA-MB-231 and Hs578T cells were transfected with plasmid DNAs encoding empty vector, pCDH, Flag-CDYL2a, or Flag-CDYL2b. After 48 h of transfection, cells were subjected to immunofluorescence staining with an antibody against Flag (red), H3K9me3 (A), heterochromatin protein 1α (HP1α) (B), SC35 (C), or fibrillarin (FBL) (D). DNA was counterstained with DAPI (blue).](thnov10p5242g004){#F4}

![**CDYL2a promotes breast cancer cell proliferation through regulating alternative splicing of FIP1L1, NKTR, and ADD3 genes.** (A) Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were subjected to RNA-seq analysis and alternative splicing events with FDR \< 0.05 and absolute ΔPSI value \> 0.1 are shown. (B) Exon skipping events within FIP1L1, NKTR, ADD3, and ATP5F1C genes are shown. (C) qPCR analysis was conducted with isoform-specific primers using MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b. The ratios of the L isoforms to all isoforms of FIP1L1, NKTR, ADD3, and ATP5F1C genes are shown. (D) qPCR analysis was performed with isoform-specific primers using BT20 and MCF-7 cells stably expressing shNC, shCDYL2\#1, or shCDYL2\#5. The ratios of the L isoforms to all isoforms of FIP1L1, NKTR, ADD3, and ATP5F1C genes are shown. (E) RT-PCR validation of individual splicing events regulated by CDYL2a. The cDNA from Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b were subjected to PCR amplification using primers flanking the alternative exon. (F) BT20 and MCF-7 cells stably expressing shNC and shCDYL2\#5 were transfected with the indicated siRNAs targeting the L isoforms of FIP1L1, NKTR, or ADD3 gene. After 48 h of transfection, cells were subjected to cell proliferation assays using CCK-8 kit. The knockdown effect of transfected siRNAs targeting the L isoforms of FIP1L1, NKTR, ADD3 genes was validated by qPCR analysis and the corresponding results are shown in [Figure S14](#SM0){ref-type="supplementary-material"}. \*, \*\*, and \*\*\* are significant differences at *p*\<0.05, *p*\<0.01, and *p*\<0.001 levels, respectively.](thnov10p5242g005){#F5}

![**CDYL2b transcriptionally represses HPSE, HLA-F, and SELL expression.** (A) Hs578T cells stably expressing pCDH, Flag-CDYL2a, and Flag-CDYL2b were subjected to RNA-seq analysis. The distribution of differentially expressed genes in CDYL2a or CDYL2b overexpressing cells is shown. (B) The percentage of upregulated or downregulated genes in CDYL2a or CDYL2b overexpressing H578T cells is shown. (C) Integrative analysis of RNA-seq and ATAC-seq results. Venn diagram showing overlapping genes (n = 38) between the downregulated genes from RNA-Seq and genes with decreased chromatin accessibility from ATAC-seq in CDYL2b overexpressing cells compared to pCDH expressing control cells. (D) RNA-seq and ATAC-seq reads around transcription starting sites of HPSE, HLA-F, and SELL genes are shown. (E) qPCR analysis of the expression levels of HPSE, HLA-F, and SELL in MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-CDYL2a, or Flag-CDYL2b. (F) qPCR analysis of the expression levels of HPSE, HLA-F, and SELL in BT20 and MCF-7 cells stably expressing shNC, shCDYL2 \#1, or shCDYL2 \#5. \*, \*\* and \*\*\*, are significant differences at *p*\<0.05, *p*\<0.01, and *p*\<0.001 levels, respectively.](thnov10p5242g006){#F6}

![**CDYL2b inhibits breast cancer cell migration and invasion through transcriptional inhibition of HPSE, HLA-F, and SELL.** (A) MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-CDYL2b, or Flag-CDYL2b were transfected with plasmid DNAs encoding HA-HPSE, HA-HLA-F, or HA-SELL. The expression status of HA-HPSE, HA-HLA-F, or HA-SELL in these cells was validated by immunoblotting with an anti-HA antibody. (B-C) The established cell lines were subjected to Boyden\'s chamber migration assays and Matrigel-coated invasion assays. Representative images of Transwell migration and invasion assays are shown in B and corresponding quantitative results are shown in C. \*, \*\* and \*\*\* are significant differences at *p*\<0.05, *p*\<0.01, and *p*\<0.001 levels, respectively.](thnov10p5242g007){#F7}
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